Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Crohn's Disease
In brief
This is a phase 2 randomized, placebo-controlled, double-blind, parallel-group multicenter induction study.
Key facts
- Study ID
- NCT03870334
- Run by
- NImmune Biopharma
- People needed
- 27
- Starts
- 2021-05-05
- Expected to finish
- 2022-08-26
- Last updated by the study team
- 2023-12-04
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study Center — Tampa, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.